News & Updates

Treatment with vedolizumab or ustekinumab leads to reduced rates of infection-related hospitalization compared with antitumour necrosis factor-α antagonists (anti-TNF) among adults with inflammatory bowel disease (IBD) initiating biologic therapy and with high comorbidity burden, reports a recent study.

The use of high-flow nasal cannula oxygen, as opposed to standard oxygen, in the first-line setting, did not reduce mortality rates in patients admitted to intensive care units (ICUs) for respiratory failure due to COVID-19, results of the SOHO-COVID trial showed.

Multiagent chemotherapy (MAC) followed by conventionally fractionated radiotherapy (CRT) shows rates of margin-negative resection (R0) and pathologic complete response similar to those of MAC plus stereotactic body radiotherapy (SBRT) in patients with localized pancreatic ductal adenocarcinoma (PDAC), according to a study. However, MAC plus CRT is associated with less regional lymphatic disease.

Use of proton pump inhibitors (PPI) appears to increase the risk of developing gastrointestinal malignancies such as gastric, pancreatic, colorectal, and liver cancer, a study has shown.

There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.

COVID-19 vaccines do not appear to carry any increased risk of developing herpes zoster infection among recipients, a study has reported.

The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.

Treatment with relugolix combination for up to 52 weeks yields sustained reductions in heavy menstrual bleeding as well as subsequent increases in iron stores in women with uterine leiomyomas, as shown in a study.